// App-Quantinova.ai

: FEASIBLE OUTCOME OF BLINATUMOMAB FOLLOWED BY ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ADULTS WITH RELAPSED OR REFRACTORY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA

Researchers

Presenter

  • Jae-Ho Yoon

Principal Investigators

  • Seug Yun Yoon

  • Joonyeop Lee

  • Changgon Kim

  • Ki-Seong Eom

  • Hee-Je Kim

  • Jong Wook Lee

  • Seok Lee

Medical Centers

  • Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)

  • Division of Hematology & Oncology,Department of Internal Medicine, Soonchunhyang University, College of Medicine, Seoul Hospital,Seoul,Korea, Republic Of;Department of Hematology,Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea,Seoul,Korea, Republic Of

  • Division of Hematology & Oncology,Department of Internal Medicine, Soonchunhyang University, College of Medicine, Seoul Hospital,Seoul,Korea, Republic Of

Locations

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Blinatumomab

  • Allopurinol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved